Jump to content

Samalizumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 18:30, 19 June 2017 (Updating {{infobox_drug}} (changes to verified and watched fields - updated 'KEGG_Ref') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Samalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD200
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6542H10086N1702O2102S46
Molar mass147.7 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]

Samalizumab was developed by Alexion Pharmaceuticals.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Samalizumab&oldid=786476938"